BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 1998

View Archived Issues

Diane-35 now available in Canada for treatment of acne

Read More

U.S. patent issued for Maxim's MaxVax technology

Read More

LIPID study establishes efficacy of pravastatin in patients with lower cholesterol levels

Read More

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Read More

Mechanism-of-action studies of nifekalant described

Read More

Improved antibacterial efficacy observed with OPC-20011

Read More

Microbix and Gensia Sicor terminate licensing agreement

Read More

Sonus and Daiichi terminate licensing agreement

Read More

AMBI seeks partners to develop oral nisin for H. pylori eradication

Read More

FDA approves new indications, dosing regimens for Vantin

Read More

Health Canada approves lamivudine for treatment of chronic HBV

Read More

CPMP issues positive opinion for E.U. approval of Zenapax

Read More

Pfizer announces further product launches for novel quinolone

Read More

Preclinical study results indicate feasibility of long-term administration of antihypertensive drug

Read More

Inhibitors of neovascularization (angiogenesis) patented by JT

Read More

Taisho discloses new antitumor series

Read More

Gene therapies for neuromuscular diseases pursued by Transgene and AFM

Read More

U.K. approval for new controlled-release nifedipine based on TIMERx technology

Read More

Albuterol delivered by novel MSI system enters clinical evaluation

Read More

Lead SelCID compound poised to enter phase II clinical trials for Crohn's disease

Read More

Novel injectable drug delivery technology in-licensed by Medi-Ject

Read More

Isis sublicenses technology for designing improved antisense drugs

Read More

Additional dose of 5G1.1-SC for phase IIb CPB study identified in phase I trial

Read More

Clinical anti-HIV activity of FTC correlated with intracellular levels of triphosphate

Read More

Hydroxyurea-containing salvage regimens for advanced-stage HIV infection

Read More

Lack of cardiotoxicity of SM-5887 confirmed in dogs

Read More

Advisory committee recommends approval of Celebrex for arthritis and further discussions for pain

Read More

Comparison of LT and TxA2 antagonists in asthmatic patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing